Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Metrics to compare | SERA | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipSERAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −0.6x | −0.7x | |
PEG Ratio | −0.23 | 0.00 | 0.00 | |
Price/Book | 1.4x | 1.1x | 2.6x | |
Price / LTM Sales | 1,145.4x | 10.2x | 3.4x | |
Upside (Analyst Target) | - | 186.9% | 36.2% | |
Fair Value Upside | Unlock | 6.7% | 4.1% | Unlock |